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Abstract
Heat shock protein 90 (Hsp90) was the focus of a recent meeting in the Swiss Alps, where the 
Hsp90 community met to discuss the operation and functions of this ubiquitous and essential 
molecular chaperone.
Molecular chaperones of the Hsp90 family execute the late-stage folding of a significant 
fraction of the eukaryotic cell proteome. So-called ‘ client’  proteins of Hsp90 have diverse 
cellular functions, but an overarching functional theme for many of them is an involvement 
in signal transduction. This causes several biological processes to be affected when the 
activity of Hsp90 becomes limiting. Here we summarize some of the new insights presented 
at the 5th International Conference on the Hsp90 Chaperone Machine, held recently in Les 
Diablerets, Switzerland—most notably, in regard to structural and mechanistic aspects of the 
chaperone cycle and how Hsp90 can empower evolution. The meeting also covered the 
continued development and emergent medical applications of highly selective inhibitors of 
Hsp90.
Asymmetry in Hsp90–cochaperone complexes
Hsp90 acts in cooperation with a number of accessory proteins, or cochaperones. Different 
cochaperones sequentially associate with Hsp90 as the chaperone cycle progresses; their 
roles include the regulation of Hsp90 ATPase activity and the bridging of Hsp90 to Hsp70 or 
client proteins. Not only do the different cochaperones often show preferences for different 
conformational states of Hsp90, but by binding at discrete stages of the Hsp90 cycle, they 
also exert temporal control over the conformational changes within the Hsp90–client 
complex and the residence time of the client on Hsp90. Evidence is now accumulating that 
many of these complexes are asymmetric. That is, Hsp90, a dimeric molecule (Fig. 1), 
sometimes associates with just a single cochaperone molecule, as when a single Aha1 
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molecule bridges the two subunits simultaneously to stimulate ATPase activity1, and at other 
times associates with several different cochaperones.
Johannes Buchner (Technische Universität München, Garching, Germany) described how 
fluorescence resonance energy transfer (FRET), when used in combination with analytical 
ultracentrifugation (AUC), can monitor these cochaperone exchanges during the progression 
from one Hsp90 complex to another. Cpr6 can bind simultaneously with Sti1, indicating that 
the two C-terminal MEEVD motifs in the Hsp90 dimer are capable of interacting with 
separate TPR domain–containing cochaperones. Addition of p23 and AMPPNP to the 
Hsp90–Sti1 complex resulted in a partial displacement of Sti1, with further displacement 
occurring on addition of Cpr6.
The cochaperone Sgt1 links Hsp90 function to nucleotide-binding leucine-rich repeat (NLR) 
receptors of innate immunity. In plants, Sgt1 acts together with the disease resistance protein 
Rar1, a cochaperone with tandem cysteine- and histidine-rich domains (CHORDs). Chris 
Prodromou (University of Sussex, Brighton, UK) presented the crystal structure of the 
symmetrical complex formed by the Hsp90 N-terminal domain (NTD), the CHORD II 
domain of Rar1 and the CS domain of Sgt1 (ref. 2). This symmetrical structure is believed to 
convert to an asymmetric structure, as the CHORD I and CHORD II domains of Rar1 can 
both bind the Hsp90 NTD, but only the CHORD II domain can associate with Sgt1. An 
exciting finding from this work is the unusual mechanism whereby Rar1 binding stimulates 
the Hsp90 ATPase activity. Rar1 displaces the ATP-lid from Hsp90’ s ATP binding site and, 
by physically inserting itself between each NTD of the Hsp90 dimer, prevents the NTD 
domain dimerization that had previously been considered a prerequisite for ATP hydrolysis. 
Other cochaperones may also be found to stimulate the Hsp90 ATPase in this way.
Addressing the conformational flexibility of Hsp90
Matthias Mayer (Zentrum für Molekular Biologie der Universität Heidelberg) presented 
investigations into the conformational flexibility of Hsp90 by amide hydrogen-deuterium 
exchange and mass spectrometry (HX-MS). These experiments reveal that the eukaryotic 
Hsp90s are considerably more flexible than their Escherichia coli counterpart HtpG, and this 
difference may allow cochaperones (which are absent from E. coli) to mould Hsp90 for 
interaction with its myriad of different client proteins. Sti1 binding was found to restrict 
Hsp90’ s flexibility throughout the entire length of the protein. The single molecule FRET 
analysis by Thorsten Hugel (Technische Universität München, Garching, Germany) also 
highlighted this conformational flexibility of Hsp90. It has revealed not only that the C-
terminal domains (CTDs) within the Hsp90 dimer undergo rapid association and 
dissociation3, but also that there is an anti-correlation between this dimerization and the 
dimerization of the NTDs, such that the CTDs tend to be nonassociated when the NTDs are 
dimerized and vice versa. The functional significance of this observation is still unclear.
Hsp90 and cochaperone interaction networks
Didier Picard (University of Geneva) described a comprehensive in silico protein-protein 
interaction network for Hsp90 based on existing protein interaction databases, with GO term 
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annotation clustering the proteins according to specific pathways. A prediction of this 
network has been experimentally validated in his laboratory, suggesting that the network will 
be an indispensible resource for the Hsp90 community. Picard maintains the Hsp90 
interactor database (http://www.picard.ch/downloads/downloads.htm). Brian Freeman 
(University of Illinois, Urbana) described the protein interaction network of the cochaperone 
p23/Sba1, established partly from a synthetic growth analysis screen in yeast, by crossing a 
sba1Δ mutant with ~4,500 single-gene deletion strains. Interestingly, less than one-third of 
the identified p23 interactors overlap with known interactors of Hsp90. A holistic view, 
however, showed that these p23 and Hsp90 interactors could often be traced to the same 
complex or pathway, indicating that although p23 can act independently of Hsp90, it does so 
in a manner that is frequently complementary to Hsp90 function. The study highlighted the 
importance of p23 in Golgi transport and nuclear functions, including RNA processing, 
DNA repair and replication, chromatin remodeling, telomere maintenance and transcription.
Hsp90 is controlled by regulatory phosphorylation
There is now substantial evidence that Hsp90 is the target of regulatory phosphorylation 
events. Len Neckers (National Cancer Institute (NCI), US National Institutes of Health 
(NIH), Bethesda, Maryland) outlined the discovery of two topologically related 
phosphorylation sites in the Hsp90 NTD. Phosphorylation at these sites in yeast Hsp82 and 
human Hsp90ず is mediated by homologous kinases, affects both client and cochaperone 
interactions with Hsp90, and influences the sensitivity of yeast and cancer cells to Hsp90 
inhibitors4. Several other sites of phosphorylation in the middle and CTD regions of yeast 
Hsp90 were described by Joanna Soroka and Johannes Buchner (Technische Universität 
München, Garching, Germany); the analyses of unphosphorylated and phosphomimetic 
mutant forms of Hsp90s in vivo and in vitro reveal the functional importance of these 
phosphorylation events.
Client protein recognition and stabilization
How Hsp90 recognizes the partly folded state of its client proteins and facilitates structural 
transitions within these clients are important, yet still poorly understood, aspects of Hsp90 
function. David Agard (University of California, San Francisco) described use of the 
staphylococcal nuclease deletion mutant Δ131Δ as a model client. Results from small-angle 
X-ray scattering (SAXS) and NMR show that a single Δ131Δ molecule binds the Hsp90 
dimer, stabilizing a V-shaped Hsp90 conformation (Fig. 1). FRET experiments confirm that 
ATP binding accelerates the closure of this Hsp90 dimer. In addition, a 15-Å cryo-EM 
structure of the Hsp90–Hop complex reveals how Hop blocks the Hsp90 ATPase yet 
promotes client binding via a newly discovered V-shaped Hsp90 conformation, which is 
intermediate between the apo and ATP-bound conformations (Fig. 1).
Stefan Rüdiger (Utrecht University) described the use of selective methyl labeling of 
isoleucine residues to map the binding of the client protein Tau by NMR. Tau is a 
microtubule-associated protein whose aggregation in neurons has been implicated in a 
number of neurodegenerative diseases. Binding of Tau was found to produce chemical shift 
perturbations in a region of the Hsp90 NTD not involved in known cochaperone interactions. 
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Nucleotide addition generated significant chemical shifts in other parts of the molecule, 
suggesting the intriguing possibility that the client binding site may change throughout the 
ATPase cycle in a manner that is synchronous with the conformational changes of Hsp90.
Hsp90 is thought to promote the stability of its clients, because these are generally 
destabilized when cells are treated with Hsp90 inhibitors. The meeting revealed some 
exciting new twists as to how Hsp90 can influence protein stability in vivo. Walid Houry 
(University of Toronto) reported that Hsp90 facilitates the processing of pre-ribosomal RNA 
by means of a protein stabilization ‘ cascade’ . In association with the small TPR cochaperone 
Tah1, Hsp90 first stabilizes a factor, Pih1, thereby enabling the formation of R2TP, a 
complex comprising two essential helicases, Rvb1 and Rvb2, together with Tah1 and Pih1 
(ref. 5). R2TP then in turn stabilizes Nop58, a component essential for assembly of the box 
C/D small nucleolar ribonucleoproteins (snoRNPs) that function to methylate pre-rRNA.
The p53 tumor suppressor remains one of the most tantalizing of Hsp90 clients. Mutation of 
p53, generating dysfunctional states of this largely unstructured transcription factor, is a 
major causative element in the development of human cancer. Maciej Zylicz (International 
Institute of Molecular and Cell Biology, Warsaw) outlined how wild-type p53 undergoes a 
dynamic cycling with Hsp90. Experiments in which WT p53 was used in conjunction with 
mutant forms of Hsp90 revealed that it is binding of ATP by Hsp90, not the ATPase activity 
of this chaperone, that causes the Hsp90–p53 complex to dissociate and that allows binding 
of the native p53 to the WAF1 promoter. Hsp90–p53 association triggers a conformational 
change, possibly a partial p53 unfolding, and the subsequent ATP-dependent dissociation of 
this Hsp90–p53 complex enables p53 to attain a conformation where it is capable of binding 
the promoter sequence6.
A new dimension to Hsp90 downregulation of the stress response
Hsp90 negatively regulates heat shock transcription factor (HSF). Patricija van Oosten-
Hawle (Northwestern University, Evanston, Illinois) described the cellular and organismal 
effects of overexpressing Hsp90 in different tissues of Caenorhabditis elegans. Within 
individual cell types, elevated Hsp90 suppressed the HSF-directed heat shock response. 
Unexpectedly, though, Hsp90 overexpression in one specific tissue seems to have an effect 
on the heat shock response in the organism as a whole. Although the C. elegans heat shock 
response is known to be controlled by thermosensory neurons7, it is still unknown how this 
alteration to Hsp90 levels in one tissue induces the stress response of an adjacent tissue.
Hsp90 deficiency and metazoan sterility
It has long been unclear why vertebrate species have two isoforms of cytosolic Hsp90, a heat 
shock–inducible isoform, Hsp90ず, and a constitutively expressed isoform, Hsp90せ (ref. 8). 
Hsp90ず is expressed primarily in primordial germ cells and has been identified as an 
extracellular component associated with tumor progression9. Ahmed Chadli (Medical 
College of Georgia, Augusta) described how UNC45A (also called GCUNC45) is the only 
cochaperone so far found to distinguish between human Hsp90ず and Hsp90せ, having 7–10 
times greater affinity for Hsp90ず than for Hsp90せ (ref. 10). UNC45A is required for optimal 
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transcriptional activity of the progesterone and glucocorticoid receptors. Didier Picard 
investigated why the loss of Hsp90せ in Hsp90せ−/− (Hsp90ab1−/−) mice causes embryonic 
lethality, whereas Hsp90ず seems dispensable for normal development, and found that 
Hsp90ず−/− (Hsp90aa1−/−) male mice are sterile despite having an active Hsp90せ, as their 
germ cells show evidence of a normal meiosis I until prophase but lack any subsequent 
spermatogenesis.
C. elegans has only a single cytosolic Hsp90, expressed primarily in germline cells and 
during oocyte development. It too is important in fertility. Klaus Richter (Technische 
Universität München, Garching, Germany) described RNA interference (RNAi) experiments 
that showed depletion of Sti1 caused sterility with impaired gonad development, whereas 
depletion of Hsp90 resulted in the protruding vulva (pvl) phenotypes11 previously observed 
for depletion of Cdc37.
Defects in Hsp90 mimic caloric restriction effects
Caloric restriction, defined as a reduction in energy intake without malnutrition, extends 
lifespan in species as diverse as yeast, worms, flies and rodents. In metazoans it acts by 
downregulating insulin-like growth factor (IGF) signaling12. Jill Johnson (University of 
Idaho, Moscow) revealed that a point mutation in the yeast Hsp90 is alone sufficient to 
recreate in glucose-grown cells the transcriptional responses that are normally only seen 
when cells are grown on a non-optimal carbon source (akin to caloric restriction) or starved 
for nitrogen. Yair Argon (University of Pennsylvania, Philadelphia) described how Grp94, 
the single Hsp90 family protein of the endoplasmic reticulum (ER), is essential for the 
folding of pro-IGF in a pre-Golgi compartment. Grp94−/− cells lack IGF secretion capacity 
and have a stress sensitivity rescued by the addition of exogenous IGF13,14. By influencing 
the levels of circulating IGF, Grp94 chaperone activity might prove to be a significant 
influence over the IGF-mediated signaling that drives the events of senescence and aging in 
diverse species12. Naturally occurring polymorphisms in the human Grp94 gene affecting 
the functionality of Grp94 might also be a significant cause of variation in circulating levels 
of IGF in humans.
Hsp90 empowering evolutionary change
Susan Lindquist (Whitehead Institute for Biomedical Research, Cambridge, Massachusetts) 
tackled the issue of how the protein homeostasis reservoir created by Hsp90 acts to promote 
not just phenotypic stability but also—when Hsp90 activity becomes limiting in 
development—the expression of cryptic mutations as Hsp90-contingent complex traits, with 
the latter leading to a rapid diversification of phenotypes15. She described how, by crossing 
ecologically and genetically diverse yeast strains and then analyzing their meiotic progeny, it 
is possible to correlate quantitative trait loci with high-resolution genome maps, thereby 
allowing one to ask the question of how phenotypes undergo alteration when Hsp90 activity 
levels become limiting. Remarkably, the correlations between phenotype and genotype 
improve with inhibition of Hsp90 or with stress, revealing that Hsp90 determines the 
adaptive value of preexisting genetic variation15.
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Renato Paro (ETH Zürich, Basel) outlined how environmental cues and Hsp90 might 
influence epigenetic controls over gene expression. In Drosophila, Hsp90 stabilizes trithorax 
(trx), a protein involved in maintaining the gene expression crucial for development. 
Chromatin immunoprecipitation followed by deep sequencing reveals that these two proteins 
colocalize at the chromatin regions that correlate with gene expression. Hsp90 and trx also 
colocalize at interbands and at the major heat shock puffs on polytene chromosomes after 
heat shock16. Hsp90 appears therefore to be intimately involved in relaying environmental 
signals to the network that supervises cellular identities.
Arabidopsis thaliana provides another amenable system for studying how compromised 
Hsp90 activity results in an increased phenotypic variation17 a d how Hsp90 may integrate 
growth and development with environmental cues. Jennifer Lachowiec (University of 
Washington, Seattle) described how brassinosteroids (BR) regulate essential processes in the 
growth and development of A. thaliana, binding to membrane-associated receptors that in 
turn signal to a set of downstream transcription factors. She revealed that, whereas Hsp90 
stabilizes the inactive, phosphorylated form of one of the BR-responsive transcription 
factors, closely related paralogs presumed to act redundantly with this transcription factor 
appear to be Hsp90-independent. BR pathway genes are polymorphic in divergent A. 
thaliana strains, and the diversity of altered developmental phenotypes among these strains 
appearing with compromised Hsp90 exposes these polymorphisms to natural selection.
A different approach to this theme of how Hsp90 drives evolution is to address how 
chaperones shape the evolution of protein sequence space. RNA viruses show the highest 
known rates of mutation in nature, and the essential role of Hsp90 in picornavirus replication 
is the requirement for this chaperone in capsid protein maturation18. Judith Frydman 
(Stanford University, Palo Alto, California) described how compromised Hsp90 activity 
affects the evolutionary trajectory whereby mutations appear in this model client. She 
emphasized how the frequency and the nature of mutations will tend to reflect both 
influences that are intrinsic to the protein (protein robustness, notably a preference for 
neutral changes or ‘ designable’  protein folds) as well as those that are extrinsic (chaperones, 
protein quality control machinery). Frydman then described how, when Hsp90 activity is 
compromised, amino acid substitutions decrease in frequency and become much more 
random in nature, whereas the frequency of silent mutations that slow translation increases. 
Full Hsp90 activity therefore facilitates diversity by helping to ensure that proteins evolve 
only through specific types of mutation and by disfavoring (‘ buffering against’ ) mutations 
that are detrimental.
Disease states associated with defects in Hsp90-mediated protein 
homeostasis
Evidence is increasing that certain diseases reflect a defective folding or clearance of client 
proteins by the Hsp90 system. William Balch (The Scripps Research Institute, La Jolla, 
California) described a comparative interactome analysis by MS of normal and ΔF508 
mutant forms of the cystic fibrosis (CF) transmembrane conductance regulator (CFTR) 
chloride channel, both in the absence and presence of proteostasis regulators (PRs), small 
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molecules that regulate Hsp90 function. Normally ΔF508, the CFTR mutation associated 
with the most common form of CF, causes the retention of this channel protein in the ER, 
though the exit of this mutant form from the ER to the cell surface is rescued by growth at 
low temperature. Although the interactome data revealed that the ΔF508 CFTR protein 
underwent several aberrant protein interactions, these were largely corrected upon treatment 
with PRs, in a manner that resembles the rescue of CFTR function at low temperature. 
Appropriate pharmacological manipulation of the Hsp90 chaperone system might therefore 
be able to rescue the dysfunctional folding of the ΔF508 CFTR protein, thereby providing a 
potentially new therapy for CF.
Attention also focused on tau, a protein that normally binds and stabilizes microtubules, but 
that, in a number of neurodegenerative diseases (‘ tauopathies’ ) that include Alzheimer’ s and 
Parkinson’ s, forms aggregates in neurons. Chad Dickey (University of South Florida, 
Tampa) described how the Hsp90 system can facilitate either a degradation or a stabilization 
of tau after microtubule disassembly. Either inhibition of Hsp90 or small interfering RNA 
(siRNA) downregulation of two cochaperones (p23 or FKBP51) facilitates the clearance of 
tau. Conversely, an overexpression of FKBP51 stabilizes tau, possibly by affecting tau 
kinase activity19. Full understanding of this chaperone processing of tau will clearly be 
important to the development of therapies designed to counteract the aggregation in 
neurodegenerative disease.
Hsp90 inhibitors in cancer
The ongoing development and clinical evaluation of novel Hsp90 inhibitor cancer drugs 
attests to the high interest of the pharmaceutical industry in this drug target. Both Jane 
Trepel (NCI, NIH) and Paul Workman (Institute of Cancer Research, London, UK) reviewed 
progress in this area and the challenges that confront the development of Hsp90 inhibitors to 
treat cancer. Ever since 17-allylaminodemethoxygeldanamycin (17-AAG) first entered the 
clinic 12 years ago, 16 other Hsp90 inhibitors have been, or are currently being, clinically 
evaluated. The effects of Hsp90 inhibition on both normal and tumor cell physiology are 
complex because of the wide variety of cellular processes affected by Hsp90, necessitating 
the development of new systems approaches to better evaluate and predict anti-cancer 
efficacy20. Nonetheless, several recent clinical trials have demonstrated promising activity in 
selected malignancies21. It may become necessary to develop inhibitors of various 
cochaperones and of Hsp70 family proteins that can either be administered alone or used 
synergistically with inhibitors of Hsp9022,23. Alternatively, drugs could be designed against 
a specific client. Marc Cox (University of Texas, El Paso) described a unique class of 
nuclear receptor alternate site modulators (NRAMs) that target the FKBP52 cochaperone 
dependence of the androgen receptor (AR). AR is frequently mutated to impart an enhanced 
FKBP52 dependence in late-stage prostate cancer. Cox described a lead compound that 
interacts with the AR ligand-binding domain but that does not compete with either hormone 
or coactivator binding. It thereby prevents hormone-induced AR dissociation from the 
Hsp90–FKBP52 chaperone complex and AR nuclear translocation and transcriptional 
activity.
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The development of inhibitors binding within the Hsp90 NTD continues unabated. Zhenhai 
Gao (Novartis) reviewed development of the fully synthetic, orally available NVPHSP990. 
This, unlike most other Hsp90 inhibitors, can penetrate into the brain. It is now in phase 1 
clinical trials in solid and hematological tumors. Gao also described new secreted 
biomarkers identified by an i  silico data-mining approach. Several of these have been 
validated as useful pharmacodynamic readouts of Hsp90 inhibitor activity in ivo and may 
therefore prove useful in the ongoing clinical development of Hsp90 inhibitors. Weiwen 
Ying (Synta Pharmaceuticals) described an Hsp90 inhibitor (STA-9090) that is up to 100-
fold more potent than 17-AAG. Active in vitro and in vivo against a wide range of tumor 
types, STA-9090 shows potent activity in cancers that have developed resistance to tyrosine 
kinase inhibitors. Based on encouraging signs of activity, a phase 2 study in non–small cell 
lung cancer has been expanded.
Ultimately the effectiveness of cancer drugs is often compromised by the emergence of drug 
resistance. As the ATP pocket of Hsp90 is highly conserved, part of the compelling case for 
developing NTD inhibitors that bind within this pocket rests on the belief that Hsp90 
mutations that disrupt drug binding should severely compromise chaperone function and 
therefore not be selected under drug pressure. Peter Piper (University of Sheffield, Sheffield, 
UK) described Hsp90 mutations that provide partial resistance to either radicicol24 or 17-
AAG in vivo in yeast engineered to express the human Hsp90s25. Importantly, binding of 
either drug is affected by distinct amino acid substitutions, suggesting that should resistance 
to a particular Hsp90 inhibitor develop in vivo, it is likely that sensitivity to other Hsp90 
inhibitors will be maintained.
One of the drawbacks of NTD inhibitors is that they tend to induce the cytoprotective heat 
shock response and therefore increase levels of major chaperones such as Hsp70 and Hsp90 
(ref. 26). Ultimately this may limit their clinical usefulness. Other drugs that target the 
Hsp90 CTD may show promise in this regard. Brian Blagg (University of Kansas, 
Lawrence) described the development of two distinct classes of CTD inhibitor, starting from 
the structure of the first CTD inhibitor, novobiocin. One class induces a robust heat shock 
response at nanomolar concentrations, protects neurons against toxic protein (Aせ)-induced 
apoptosis, and counteracts diabetic peripheral neuropathy27,28. A second class of CTD 
inhibitors fails to induce a heat shock response and is highly cytotoxic to tumor cells in vitro
and in vivo29. Giorgio Colombo (Instituto di Chimica del Riconoscimento Moleculare, 
Milan, Italy) outlined the first in silico discovery of Hsp90 inhibitors that also target the 
CTD30. Importantly, by this completely independent approach, they identified a drug 
binding site similar to that of Blagg and colleagues.
Targeting Hsp90 to treat infectious diseases
Finally, it is now apparent that Hsp90 inhibitor drugs will likely have a clinical utility 
beyond cancer. A number of parasitic diseases seem very amenable to these agents. Leah 
Cowen (University of Toronto) described how abrogating Hsp90 function is a promising 
strategy to counteract both the virulence and the emergence of drug resistance by fungal 
pathogens. In the major human pathogen Ca dida albicans, Hsp90 can promote resistance to 
two widely deployed classes of antifungal drugs, the azoles and the echinocandins31,32, via 
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its influence on calcineurin or protein kinase C signaling pathways. The morphogenetic 
switching of C. albicans from its yeast to its hyphal state (filamentation), a key determinant 
of virulence, can be triggered by combined heat and serum treatment. Hsp90 inhibitors can 
bypass the temperature requirement for filamentation that relies on the Ras–protein kinase A 
pathway33. Selective downregulation of C. albicans Hsp90, using a tetracycline (Tet) 
promoter–regulated Hsp90 gene, led to a clearance of the fungal burden in systemically 
infected mice33.
Hsp90 is also a promising target for antimalarial drug development. Both Utpal Tatu (Indian 
Institute of Science, Bangalore, India) and Dylan Pillai (University of Toronto) described the 
antimalarial activity of Hsp90 inhibitors. 17-AAG, the Hsp90 inhibitor that has undergone 
extensive clinical trials in cancer patients, has proven effective in preventing parasite growth 
in human erythrocytes and in a mouse model34. PU-H71, another inhibitor in clinical 
evaluation in cancer patients, is also an effective inhibitor of malaria Hsp90. Using high-
throughput screening, Pillai identified three malaria-specific Hsp90 inhibitors that kill 
parasites at nanomolar concentrations in vitro and synergize with the anti-malarial drug 
chloroquine35. Importantly, these compounds were able to kill a multi-drug-resistant clinical 
isolate of malaria that demonstrated reduced responsiveness to artemisinin, the anti-malarial 
currently recommended by the World Health Organization.
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A model of Hsp90 client loading.
(a) EM structure of the apo-state. (b) EM structure of the Hsp90–Hop complex. (c) The 
NMR, SAXS and FRET data for the staphylococcal nuclease Δ131Δ-loaded Hsp90. (d) A 
hypothetical model of client loading on Hsp90 via Hsp70 and Hop. (e) Final closed ATP-
bound conformation.
Structures a, b and c suggest a common structural pathway for both client-driven and 
cochaperone-driven loading of client proteins to the Hsp90 dimer via a V-shaped structure (b 
and c); the latter being intermediate between the apo form a and the final closed ATP-bound 
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conformation e. Figure courtesy of D. Southworth, T. Street and D. Agard, University of 
California, San Francisco.
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